{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:51:13Z","timestamp":1774281073018,"version":"3.50.1"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["DS 23"],"award-info":[{"award-number":["DS 23"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.neubiorev.2020.04.020","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T23:05:04Z","timestamp":1589151904000},"page":"158-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Contribution of CB2 receptors in schizophrenia-related symptoms in various animal models: Short review"],"prefix":"10.1016","volume":"114","author":[{"given":"Izabela","family":"Banaszkiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazyna","family":"Biala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Kruk-Slomka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/schbul\/sbr133","article-title":"Is the acute NMDA receptor hypofunction a valid model of schizophrenia?","volume":"38","author":"Adell","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"14","key":"10.1016\/j.neubiorev.2020.04.020_bib0010","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2174\/092986708784567716","article-title":"Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists","volume":"15","author":"Ashton","year":"2008","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.04.020_bib0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1476-5381.2010.00729.x","article-title":"CB2: a cannabinoid receptor with an identity crisis","volume":"160","author":"Atwood","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/7854_2015_376","article-title":"Mechanisms underlying motivational deficits in psychopathology: similarities and differences in depression and schizophrenia","volume":"27","author":"Barch","year":"2016","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"2","key":"10.1016\/j.neubiorev.2020.04.020_bib0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1037\/0735-7044.107.2.363","article-title":"Neonatal capsaicin exposure affects isolation-induced aggressive behavior and hypothalamic substance P levels of adult male mice (Mus musculus)","volume":"107","author":"Bigi","year":"1993","journal-title":"Behav. Neurosci."},{"issue":"1-3","key":"10.1016\/j.neubiorev.2020.04.020_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-2999(03)01274-3","article-title":"The mouse light\/dark box test","volume":"463","author":"Bourin","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.biopsych.2004.12.030","article-title":"Female schizophrenia patients have prepulse inhibition deficits","volume":"57","author":"Braff","year":"2005","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2020.04.020_bib0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/1471-244X-12-221","article-title":"Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?","volume":"5","author":"Bramness","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pbb.2019.05.010","article-title":"Increased sensitivity to psychostimulants and GABAergic drugs in Lsamp-deficient mice","volume":"183","author":"Bregin","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0050","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1176\/appi.ajp.159.9.1528","article-title":"Paternal age and risk of schizophrenia in adult offspring","volume":"159","author":"Brown","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0055","article-title":"Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons","volume":"15","author":"Canseco-Alba","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1192\/bjp.182.2.117","article-title":"Migration as a risk factor for schizophrenia: a Danish population-based cohort study","volume":"182","author":"Cantor-Graae","year":"2003","journal-title":"Br. J. Psychiatry"},{"issue":"Suppl., 4","key":"10.1016\/j.neubiorev.2020.04.020_bib0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/PL00014183","article-title":"Neurotransmitter interactions in schizophrenia-therapeutic implications","volume":"249","author":"Carlsson","year":"1999","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"21-22","key":"10.1016\/j.neubiorev.2020.04.020_bib0070","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1007\/s00213-015-3946-6","article-title":"PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments","volume":"232","author":"Casta\u00f1\u00e9","year":"2015","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0075","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.psyneuen.2011.12.014","article-title":"Personality traits in rats predict vulnerability and resilience to developing stress-induced depression-like behaviors, HPA axis hyper-reactivity and brain changes in pERK1\/2 activity","volume":"37","author":"Castro","year":"2012","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"10.1016\/j.neubiorev.2020.04.020_bib0080","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9040093","article-title":"Descriptive psychopathology of the acute effects of intravenous Delta-9-Tetrahydrocannabinol administration in humans","volume":"9","author":"Colizzi","year":"2019","journal-title":"Brain Sci."},{"issue":"5","key":"10.1016\/j.neubiorev.2020.04.020_bib0085","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/schbul\/sbs076","article-title":"NMDA receptor and schizophrenia: a brief history","volume":"38","author":"Coyle","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.neubiorev.2020.04.020_bib0090","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00213-009-1663-8","article-title":"Modelling psychosis","volume":"206","author":"Curran","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-511X-2-5","article-title":"Endocannabinoid signalling in the blood of patients with schizophrenia","volume":"2","author":"De Marchi","year":"2003","journal-title":"Lipids Health Dis."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.04.020_bib0100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.physbeh.2004.01.013","article-title":"Behaviour in the elevated plus-maze predicts coping after subchronic mild stress in mice","volume":"81","author":"Ducottet","year":"2004","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0105","doi-asserted-by":"crossref","first-page":"10404","DOI":"10.1523\/JNEUROSCI.1618-08.2008","article-title":"D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801","volume":"28","author":"Errico","year":"2008","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0110","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12035-016-9697-5","article-title":"Role of the endocannabinoid system in the pathophysiology of schizophrenia","volume":"54","author":"Fakhoury","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2011.09.010","article-title":"Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801","volume":"62","author":"Farley","year":"2012","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bbr.2007.12.032","article-title":"A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory","volume":"189","author":"Featherstone","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"Suppl. 2","key":"10.1016\/j.neubiorev.2020.04.020_bib0125","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/j.rbp.2012.07.003","article-title":"The endocannabinoid system and its role in schizophrenia: a systematic review of the literature","volume":"34","author":"Ferretjans","year":"2012","journal-title":"Braz. J. Psychiatry."},{"issue":"2","key":"10.1016\/j.neubiorev.2020.04.020_bib0130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s40473-014-0013-2","article-title":"Animal models of psychosis: current state and future directions","volume":"1","author":"Forrest","year":"2014","journal-title":"Curr. Behav. Neurosci. Rep."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.04.020_bib0135","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.neuropharm.2011.02.007","article-title":"Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia","volume":"62","author":"Gandal","year":"2012","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2020.04.020_bib0140","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1476-5381.2011.01625.x","article-title":"Chronic blockade of cannabinoid CB(2) receptors induces anxiolytic-like actions associated to alterations in GABA(A) receptors","volume":"165","author":"Garcia-Gutierrez","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0269881110379507","article-title":"Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice","volume":"25","author":"Garcia-Gutierrez","year":"2011","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0150","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s13311-018-0610-y","article-title":"Alterations in gene and protein expression of cannabinoid CB2 and GPR55 receptors in the dorsolateral prefrontal cortex of suicide victims","volume":"15","author":"Garcia-Gutierrez","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0155","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.neuropharm.2013.05.034","article-title":"Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors","volume":"73","author":"Garcia-Gutierrez","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0160","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1476-5381.2010.00819.x","article-title":"Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors","volume":"160","author":"Garcia-Gutierrez","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2005.11.035","article-title":"Cannabinoid CB2 receptors: immunohistochemical localization in rat brain","volume":"1071","author":"Gong","year":"2006","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.neubiorev.2020.04.020_bib0170","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145709009961","article-title":"Sensitivity to MK-801 in phospholipase C-beta1 knockout mice reveals a specific NMDA receptor deficit","volume":"12","author":"Gray","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0175","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s002130050038","article-title":"Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice","volume":"148","author":"Griebel","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"issue":"10","key":"10.1016\/j.neubiorev.2020.04.020_bib0180","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1177\/0269881112441865","article-title":"Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats","volume":"26","author":"Gururajan","year":"2012","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0185","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9804836","article-title":"From onset and prodromal stage to a life-long course of schizophrenia and its symptom dimensions: how sex, age, and other risk factors influence incidence and course of illness","author":"H\u00e4fner","year":"2019","journal-title":"Psychiatry J."},{"issue":"2","key":"10.1016\/j.neubiorev.2020.04.020_bib0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.tips.2006.12.004","article-title":"The emerging functions of endocannabinoid signaling during CNS development","volume":"28","author":"Harkany","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0195","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(03)12379-3","article-title":"Genes for schizophrenia? Recent findings and their pathophysiological implications","volume":"361","author":"Harrison","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.neubiorev.2020.04.020_bib0200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/wcs.1253","article-title":"Cognitive aspects of schizophrenia","volume":"4","author":"Harvey","year":"2013","journal-title":"Wiley Interdiscip. Rev. Cogn. Sci."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0205","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0278-5846(00)00151-2","article-title":"The mouse light-dark paradigm: a review","volume":"25","author":"Hasco\u00ebt","year":"2001","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2020.04.020_bib0210","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.neubiorev.2012.07.001","article-title":"Neurobiology of chronic mild stress: parallels to major depression","volume":"36","author":"Hill","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.neubiorev.2020.04.020_bib0215","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0220","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.apha.2017.03.007","article-title":"CB1 and CB2Receptor Pharmacology","volume":"80","author":"Howlett","year":"2017","journal-title":"Adv. Pharmacol."},{"issue":"8","key":"10.1016\/j.neubiorev.2020.04.020_bib0225","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23081836","article-title":"Cannabinoid CB2 receptor gene and environmental interaction in the development of psychiatric disorders","volume":"23","author":"Ishiguro","year":"2018","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.neubiorev.2020.04.020_bib0230","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.biopsych.2009.09.024","article-title":"Brain cannabinoid CB2 receptor in schizophrenia","volume":"67","author":"Ishiguro","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2020.04.020_bib0235","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/sj.tpj.6500431","article-title":"Involvement f cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans","volume":"7","author":"Ishiguro","year":"2007","journal-title":"Pharmacogenomics J."},{"issue":"8","key":"10.1016\/j.neubiorev.2020.04.020_bib0240","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1017\/S0033291708003152","article-title":"Signs and symptoms in the pre-psychotic phase: description and implications for diagnostic trajectories","volume":"38","author":"Iyer","year":"2008","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0245","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neuropharm.2017.09.014","article-title":"Maslinic acid ameliorates NMDA receptor blockade-induced schizophrenia-like behaviors in mice","volume":"126","author":"Jeon","year":"2017","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2020.04.020_bib0250","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"15","key":"10.1016\/j.neubiorev.2020.04.020_bib0255","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1002\/hbm.24716","article-title":"Brain-based ranking of cognitive domains to predict schizophrenia","volume":"40","author":"Karrer","year":"2019","journal-title":"Hum. Brain Mapp."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.04.020_bib0260","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.psychres.2014.12.006","article-title":"Comorbid substance use disorders in schizophrenia: a latent class approach","volume":"225","author":"Kerner","year":"2015","journal-title":"Psychiatry Res."},{"issue":"16","key":"10.1016\/j.neubiorev.2020.04.020_bib0265","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1007\/s00213-014-3481-x","article-title":"CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice","volume":"231","author":"Khella","year":"2014","journal-title":"Psychopharmacology (Berl.)"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0270","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/oxim.3.1.10028","article-title":"Clinical physiology and mechanism of dizocilpine (MK-801): electron transfer, radicals, redox metabolites and bioactivity","volume":"3","author":"Kovacic","year":"2010","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"7","key":"10.1016\/j.neubiorev.2020.04.020_bib0275","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/ejp.1377","article-title":"Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders","volume":"23","author":"Krebs","year":"2019","journal-title":"Eur. J. Pain"},{"issue":"3","key":"10.1016\/j.neubiorev.2020.04.020_bib0280","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12640-017-9702-4","article-title":"The impact of CB2 receptor ligands on the MK-801-Induced hyperactivity in mice","volume":"31","author":"Kruk-Slomka","year":"2017","journal-title":"Neurotox. Res."},{"issue":"11","key":"10.1016\/j.neubiorev.2020.04.020_bib0285","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1007\/s12035-019-1596-0","article-title":"Effects of fatty acid amide hydrolase inhibitors acute administration on the positive and cognitive symptoms of schizophrenia in mice","volume":"56","author":"Kruk-Slomka","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.neubiorev.2020.04.020_bib0290","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12640-016-9662-0","article-title":"The influence of the CB1 receptor ligands on the schizophrenia-like effects in mice induced by MK-801","volume":"30","author":"Kruk-Slomka","year":"2016","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0295","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12888-015-0562-2","article-title":"Common or distinct pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk factors and antecedents of the schizophrenia spectrum disorders and affective psychoses","volume":"15","author":"Laurens","year":"2015","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2020.04.020_bib0300","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1503\/jpn.100054","article-title":"Contribution of nonprimate animal models in understanding the etiology of schizophrenia","volume":"36","author":"Lazar","year":"2011","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2020.04.020_bib0310","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"20","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0315","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.neuro.25.112701.142754","article-title":"Schizophrenia as a disorder of neurodevelopment","volume":"25","author":"Lewis","year":"2002","journal-title":"Annu Rev Neurosci."},{"issue":"10","key":"10.1016\/j.neubiorev.2020.04.020_bib0320","doi-asserted-by":"crossref","first-page":"pyv046","DOI":"10.1093\/ijnp\/pyv046","article-title":"Changed synaptic plasticity in neural circuits of depressive-like and escitalopram-treated rats","volume":"18","author":"Li","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.04.020_bib0325","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0893-133X(00)00137-8","article-title":"To model a psychiatric disorder in animals: schizophrenia as a reality test","volume":"23","author":"Lipska","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0330","doi-asserted-by":"crossref","first-page":"17410","DOI":"10.1038\/s41598-017-17796-y","article-title":"Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0335","doi-asserted-by":"crossref","first-page":"9865","DOI":"10.1038\/s41598-019-46109-8","article-title":"Onset of schizophrenia diagnoses in a large clinical cohort","volume":"9","author":"Lopez-Castroman","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpr.2019.101746","article-title":"The relevance of cognitive emotion regulation to psychotic symptoms - A systematic review and meta-analysis","volume":"72","author":"Ludwig","year":"2019","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0345","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fnbeh.2016.00202","article-title":"Reduced prepulse inhibition as a biomarker of schizophrenia","volume":"10","author":"Mena","year":"2016","journal-title":"Front. Behav. Neurosci."},{"issue":"June (5)","key":"10.1016\/j.neubiorev.2020.04.020_bib0350","article-title":"Measuring disturbance of the endocannabinoid system in psychosis: a systematic review and meta-analysis","author":"Minichino","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0355","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1192\/bjp.bp.107.046649","article-title":"Effects of cannabidiol on schizophrenia like symptoms in people who use cannabis","volume":"192","author":"Morgan","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0360","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hup.1166","article-title":"Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation","volume":"26","author":"Morrison","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0365","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.euroneuro.2008.04.002","article-title":"Schizophrenia: from developmental deviance to dopamine dysregulation","volume":"3","author":"Murray","year":"2008","journal-title":"Eur. Neuropsychopharmacol. Suppl"},{"issue":"6","key":"10.1016\/j.neubiorev.2020.04.020_bib0370","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/npp.2017.270","article-title":"S-ketamine-Induced NMDA receptor blockade during natural speech production and its implications for formal thought disorder in schizophrenia: a Pharmaco-fMRI study","volume":"43","author":"Nagels","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0375","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1196\/annals.1432.036","article-title":"Functional expression of brain neuronal CB2 cannabinoid receptors are involved in theeffects of drugs of abuse and in depression","volume":"1139","author":"Onaivi","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0380","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1196\/annals.1369.052","article-title":"Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain","volume":"1074","author":"Onaivi","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0385","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1460-9568.2003.02436.x","article-title":"Impact of high and low anxiety on cognitive performance in a modified hole board test in C57BL\/6 and DBA\/2 mice","volume":"17","author":"Ohl","year":"2003","journal-title":"Eur J Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0390","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/0269881111400652","article-title":"CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity","volume":"26","author":"Onaivi","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0395","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/npp.2011.34","article-title":"Stimulus quality affects expression of the acoustic startle response and prepulse inhibition in mice","volume":"36","author":"Ortega-Alvaro","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109666","article-title":"Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia","volume":"95","author":"Osborne","year":"2019","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1-2","key":"10.1016\/j.neubiorev.2020.04.020_bib0405","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2009.11.005","article-title":"Stress induced cognitive deficit is differentially modulated in BALB\/c and C57Bl\/6 mice: correlation with Th1\/Th2 balance after stress exposure","volume":"218","author":"Palumbo","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.neubiorev.2020.04.020_bib0410","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1192\/bjp.2019.140","article-title":"When the drugs don\u2019t work: the potential of glutamatergic antipsychotics in schizophrenia - ADDENDUM","volume":"215","author":"Papanastasiou","year":"2019","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2020.04.020_bib0415","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41401-018-0073-z","article-title":"Developmental and behavioral effects in neonatal and adult mice following prenatal activation of endocannabinoid receptors by capsaicin","volume":"40","author":"Perchuk","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0420","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0079-6123(09)17905-0","article-title":"Inducible and conditional transgenic mouse models of schizophrenia","volume":"179","author":"Pletnikov","year":"2009","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0425","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2019.06.011","article-title":"Using proton magnetic resonance spectroscopic imaging to study glutamatergic alterations in patients with schizophrenia: a systematic review","volume":"210","author":"Plitman","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0430","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbr.2004.04.008","article-title":"Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress","volume":"155","author":"Pothion","year":"2004","journal-title":"Behav. Brain Res."},{"issue":"46","key":"10.1016\/j.neubiorev.2020.04.020_bib0435","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1523\/JNEUROSCI.3400-08.2008","article-title":"Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain","volume":"28","author":"Racz","year":"2008","journal-title":"J. Neurosci."},{"issue":"47","key":"10.1016\/j.neubiorev.2020.04.020_bib0440","article-title":"The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue","volume":"5","author":"Brisch","year":"2014","journal-title":"Front. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2020.04.020_bib0445","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/mp.2012.23","article-title":"Neurodevelopmental model of schizophrenia: update","volume":"17","author":"Rapoport","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2020.04.020_bib0450","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.phrs.2009.03.006","article-title":"Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids","volume":"60","author":"Realini","year":"2009","journal-title":"Pharmacol. Res."},{"issue":"1-2 Suppl 1","key":"10.1016\/j.neubiorev.2020.04.020_bib0455","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.mce.2008.02.003","article-title":"Long lasting consequences of cannabis exposure in adolescence","volume":"286","author":"Rubino","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"issue":"5","key":"10.1016\/j.neubiorev.2020.04.020_bib0460","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/schbul\/sbr090","article-title":"Aggression in schizophrenia","volume":"37","author":"Serper","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0465","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2045125314557797","article-title":"Drug models of schizophrenia","volume":"5","author":"Steeds","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.04.020_bib0470","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1017\/S0033291713000883","article-title":"Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation","volume":"44","author":"Stone","year":"2014","journal-title":"Psychol. Med. (Paris)"},{"issue":"7","key":"10.1016\/j.neubiorev.2020.04.020_bib0475","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1744-9081-7-9","article-title":"Update in the methodology of the chronic stress paradigm: internal control matters","volume":"27","author":"Strekalova","year":"2011","journal-title":"Behav. Brain Funct."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0480","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/archpsyc.63.12.1325","article-title":"Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function","volume":"63","author":"Swerdlow","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0485","first-page":"104","article-title":"Light\/dark transition test for mice","volume":"13","author":"Takao","year":"2006","journal-title":"J. Vis. Exp. Nov"},{"issue":"suppl 40","key":"10.1016\/j.neubiorev.2020.04.020_bib0490","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/bjp.178.40.s18","article-title":"Genes, environment and schizophrenia","volume":"187","author":"Tsuang","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109038","article-title":"Behavioural effects of inhalation exposure to dizocilpine (MK-801) in mice","volume":"117","author":"Ueno","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.neubiorev.2020.04.020_bib0500","first-page":"240","article-title":"Depression and schizophrenia: cause, consequence, or trans-diagnostic issue?","volume":"43","author":"Upthegrove","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.neubiorev.2020.04.020_bib0505","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1017\/S1461145709000388","article-title":"Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation","volume":"12","author":"Van den Buuse","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.neubiorev.2020.04.020_bib0510","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/aje\/kwf043","article-title":"Cannabis use and psychosis: a longitudinal population-based study","volume":"156","author":"Van Os","year":"2002","journal-title":"Am. J. Epidemiol."},{"issue":"5746","key":"10.1016\/j.neubiorev.2020.04.020_bib0515","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.neubiorev.2020.04.020_bib0520","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/npp.2011.321","article-title":"Delay- and dose-dependent effects of \u03949-tetrahydrocannabinol administration on spatial and object working memory tasks in adolescent rhesus monkeys","volume":"37","author":"Verrico","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"June (5)","key":"10.1016\/j.neubiorev.2020.04.020_bib0525","article-title":"Insights into the pathophysiology of endocannabinoid signaling in schizophrenia","author":"Volk","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0530","article-title":"D2 receptor-mediated miRNA-143 expression is associated with the effects of antipsychotic drugs on phencyclidine-induced schizophrenia-related locomotor hyperactivity and with Neuregulin-1 expression in mice","volume":"21","author":"Wang","year":"2019","journal-title":"Neuropharmacology. Jun"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0535","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","article-title":"Pathway-specific dopamine abnormalities in schizophrenia","volume":"81","author":"Weinstein","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.04.020_bib0540","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/YCO.0000000000000122","article-title":"Reward processing dysfunction in major depression, bipolar disorder and schizophrenia","volume":"28","author":"Whitton","year":"2015","journal-title":"Curr. Opin. Psychiatry"},{"issue":"January (1)","key":"10.1016\/j.neubiorev.2020.04.020_bib0545","article-title":"Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse","volume":"2018","author":"Williams","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0550","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000087097","article-title":"Chronic mild stress (CMS) revisited: consistency and behavioural neurobiological concordance in the effects of CMS","volume":"52","author":"Willner","year":"2005","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0555","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ynstr.2016.08.002","article-title":"The chronic mild stress (CMS) model of depression: history, evaluation and usage","volume":"6","author":"Willner","year":"2017","journal-title":"Neurobiol. Stress"},{"issue":"12","key":"10.1016\/j.neubiorev.2020.04.020_bib0560","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw080","article-title":"Antidepressant effects of (+)-MK-801 and (-)-MK-801 in the social defeat stress model","volume":"19","author":"Yang","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0565","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0166-4328(03)00107-4","article-title":"Anxiety-related behavior and densities of glutamate, GABAA, acetylcholine and serotonin receptors in the amygdala of seven inbred mouse strains","volume":"145","author":"Yilmazer-Hanke","year":"2003","journal-title":"Behav Brain Res."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.04.020_bib0570","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.neuropharm.2011.06.013","article-title":"Mouse pharmacological models of cognitive disruption relevant to schizophrenia","volume":"62","author":"Young","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neubiorev.2020.04.020_bib0575","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/bmj.325.7374.1199","article-title":"Selfreported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study","volume":"325","author":"Zammit","year":"2002","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.neubiorev.2020.04.020_bib0580","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/YCO.0b013e328336661b","article-title":"The relevance of reward pathways for schizophrenia","volume":"23","author":"Ziauddeen","year":"2010","journal-title":"Curr. Opin. Psychiatry"}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763419308929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763419308929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:40:14Z","timestamp":1758966014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763419308929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":116,"alternative-id":["S0149763419308929"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2020.04.020","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of CB2 receptors in schizophrenia-related symptoms in various animal models: Short review","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2020.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}